Table 2.
Neuropsychological performances of MCI-AD and MCI-S patients at baseline and follow-up
| Test | MCI-S |
MCI-AD |
||||
|---|---|---|---|---|---|---|
| Baseline | Follow-up | P | Baseline | Follow-up | P | |
| MMSE | 27.30 (2.31) | 27.15 (2.86) | .76 | 25.18 (2.99) | 25.09 (3.47) | .90 |
| CAMCOG | 91.07 (7.61) | 91.69 (11.09) | .81 | 81.27 (7.15) | 82.18 (7.99) | .65 |
| VF | 12.57 (3.37) | 13.50 (3.23) | .14 | 10.41 (2.99) | 10.50 (2.84) | .92 |
| TMT-A | 73.46 (39.95) | 65.28 (28.97) | .18 | 72.16 (41.77) | 97.00 (13.69) | .04 |
| TMT-B | 152.44 (55.48) | 157.85 (73.82) | .60 | 167.55 (60.45) | 228.44 (94.33) | .05 |
| FOME | 40.42 (4.10) | 39.67 (7.60) | .60 | 38.00 (9.21) | 31.66 (9.41) | <.01 |
| SKT | 3.35 (2.83) | 4.17 (6.09) | .49 | 6.92 (4.09) | 9.00 (4.39) | .02 |
Abbreviations: MCI-AD, mild cognitive impairment subjects who progressed to Alzheimer's disease; MCI-S, stable cases of MCI; MMSE, mini-mental state examination; CAMCOG, cognitive test Cambridge; VF, verbal fluency test; TMT-A and -B, trail making test A and B; FOME, Fuld object memory evaluation; SKT, short cognitive test.
NOTE. Values are presented as means and standard deviation.